Here, we found that the anticancer effect of vitamin C can be potentiated in different in vitro and in vivo mouse models by STS/FMD treatment selectively in KRAS-mutant cancers, through a mechanism that is independent of glucose, but that involves differential regulation of HO-1. The gene discussed is KRAS; the disease is cancer.